Resveratrol
PolyphenolAlso known as: Trans-resveratrol · 3,5,4'-trihydroxystilbene
A polyphenol found in red grape skins that activates SIRT1 (sirtuins). Extensively studied for longevity, cardiovascular health, and insulin sensitivity. Bioavailability is low and human clinical evidence is mixed.
How expert claims hold up
13 of 26 claims assessed1 of 13 assessed claims supported or partially supported by published research
Evidence Summary
The available research on resveratrol spans multiple health domains — including metabolic health, bone density, cardiovascular function, liver disease, and aging — but the overall evidence base is fragmented and largely insufficient to draw firm conclusions. The 15 studies provided include a mix of narrative reviews, a small number of RCTs, and two meta-analyses, covering diverse populations and outcomes without a consistent focus. While resveratrol is a well-characterized polyphenol found naturally in grapes, red wine, blueberries, and peanuts, translating its promising preclinical profile into demonstrated human benefits has proven difficult. Of 13 expert claims evaluated, 12 were rated as having insufficient evidence, and only one — describing resveratrol's natural food sources — was even partially supported.
Read full evidence summary →Top studies
Efficacy of dietary supplements on improving sleep quality: a systematic review and meta-analysis.
Efficacy of dietary supplements on improving sleep quality: a systematic review and meta-analysis.
Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Expert Mentions
All 26 mentions"This 'antioxidant paradox' is something I take seriously."
Patrick takes seriously the 'antioxidant paradox' — the concern that resveratrol's antioxidant activity may suppress beneficial ROS signaling from exercise.
None of the 10 provided studies directly address the 'antioxidant paradox' concern — specifically, whether resveratrol's antioxidant activity blunts beneficial reactive oxygen species (ROS) signaling triggered by exercise. The retrieved literature covers resveratrol in contexts such as diabetes management (PMID: 35240291), NAFLD (PMID: 36159792), caloric restriction mimicry (PMID: 22055504), and vascular effects (PMID: 30934670), but none specifically examines the interaction between resveratrol supplementation and exercise-induced ROS signaling adaptations. The hormesis review (PMID: 38182079) is conceptually adjacent but is not reported with sufficient detail to confirm it addresses this specific mechanism.
"This 'antioxidant paradox' is something I take seriously."
Patrick takes seriously the 'antioxidant paradox' — the concern that resveratrol's antioxidant activity may suppress beneficial ROS signaling from exercise.
Key findings
- ·Resveratrol is a naturally occurring polyphenol present in red wine, grapes, blueberries, and peanuts — this basic biochemical fact is well established.
- ·A small number of RCTs suggest possible benefits for bone mineral density in postmenopausal women and for metabolic markers in type 2 diabetes, but these trials are individually of moderate quality and limited in size.
- ·Meta-analytic evidence for polyphenol supplementation in non-alcoholic fatty liver disease is rated strong in quality, but resveratrol's specific contribution within that class of compounds remains unclear.
Evidence gaps
- ·Nearly all outcome areas — including cognitive health, endometriosis, preeclampsia prevention, and cancer chemoprevention — lack dedicated, high-quality human RCTs specifically testing resveratrol, leaving major uncertainty about real-world efficacy.
- ·Optimal dosing, duration, and bioavailability of resveratrol in humans are not well defined by the available studies, making it difficult to translate any positive findings into practical supplementation guidance.
- ·Long-term safety data in diverse human populations is absent from the current evidence base; most safety observations come from short-duration trials or descriptive reviews rather than controlled long-term studies.